High mobility group box 1 pseudogene 33 (HMGB1P33)

HMGB1P33 is a pseudogene related to the high mobility group box 1 (HMGB1) gene family[1]. Pseudogenes are genomic DNA sequences similar to normal genes but are typically nonfunctional; they arise from gene duplication or retrotransposition events[3]. While functional protein-coding HMGB1 plays a role in chromatin architecture and has been implicated in inflammation and cancer as a biological target, HMGB1P33 does not encode a functional protein and is not considered a druggable target or receptor[1][3]. Some pseudogenes in this family have been reported as regulatory elements at the RNA level (acting as molecular sponges or decoys for miRNAs, affecting the canonical gene's expression), but there is no specific evidence that HMGB1P33 acts in this way[1][3]. No direct disease associations, drug interactions, or biomarker utility have been documented for HMGB1P33. HMGB1P33 is a pseudogene, not a therapeutic target (such as a receptor, enzyme, transporter, or transcription factor)[1][3]. No functional, clinical, or pharmacological data exist for HMGB1P33 to support its use in drug discovery or therapy. Its only known role is as a non-functional genetic element related to the HMGB1 gene family. HMGB1P33 is a non-coding pseudogene and should not be considered a molecular therapeutic target or receptor. No biologically significant or disease-related information specific to HMGB1P33 is available in current literature or gene databases[1][3].

Other names

HMGB1P33

Not applicable